Unlocking IL-2's Potential

Unlocking the Immune System: Investigating a Re-engineered Approach to Treat Cancer

This sponsored article, featuring Craig Hopkinson, M.D., Alkermes' Chief Medical Officer, originally appeared in Scrip in December 2021. In November 2023, Alkermes completed the separation of its oncology business into Mural Oncology plc, a new, independent, publicly traded company. Visit www.muraloncology.com to learn more.

Executive Summary

The unmet medical need in oncology is changing. While immunotherapies have transformed the treatment of some cancers, they are only available to, and effective in, a small subset of patients. Bringing the power of immunotherapies to more patients is now the defining challenge of oncology R&D. Recognizing that, Alkermes is using R&D capabilities honed over 30 years of work on complex, hard-to-treat diseases to investigate a potential next breakthrough in cancer therapy.

Read the full article